Emisphere Technologies, Inc. and Novo Nordisk have entered into an exclusive development and license agreement to develop and commercialize oral formulations of Novo Nordisk’s insulins using Emisphere’s Eligen Technology. Emisphere will receive $5 million upfront and is eligible to receive $57.5 million in potential product development and sales milestone payments, as well as royalties. “This is an encouraging agreement on a promising technology for oral administration of p...